G01N 2333/70553
Integrin beta2-subunit-containing molecules
Official title: Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
G01N2333/70553 (Integrin beta2-subunit-containing molecules) appears on 29 US grants and 64 published applications in this corpus.
Search patents in G01N- Granted patents
- 29
- Published applications
- 64
- Assignees
- 49
- Inventors
- 115
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 2 | 2 |
| 2003 | 1 | 2 |
| 2004 | 0 | 0 |
| 2005 | 1 | 2 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 1 | 2 |
| 2009 | 0 | 3 |
| 2010 | 1 | 0 |
| 2011 | 2 | 4 |
| 2012 | 0 | 2 |
| 2013 | 3 | 4 |
| 2014 | 3 | 3 |
| 2015 | 1 | 6 |
| 2016 | 4 | 7 |
| 2017 | 0 | 2 |
| 2018 | 2 | 2 |
| 2019 | 1 | 3 |
| 2020 | 1 | 3 |
| 2021 | 0 | 2 |
| 2022 | 0 | 5 |
| 2023 | 2 | 0 |
| 2024 | 1 | 2 |
| 2025 | 1 | 2 |
| 2026 | 1 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- TCR-independent molecular identification of mutation-related and tumor-specific T cells17 Mar 2026US 12,578,332 B2Medizinische Hochschule Hannover
- Peripheral blood biomarker for evaluating anti-tumor immune effect of radiation therapy14 Oct 2025US 12,442,820 B2Saitama Medical University
- Method of examining possibility of subject having pancreatic cancer23 Apr 2024US 11,965,887 B2THEORIA Science Inc.
- Antibody therapies and methods for treating coronavirus infection21 Feb 2023US 11,584,792 B2Trustees of Boston University
- Compositions and methods for in vitro assays of fibrin activity7 Feb 2023US 11,573,222 B2The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
- Use of extracellular vesicles and micronuclei of circulating stromal cells as pan-cancer biomarkers for predicting clinical outcomes12 Mar 2026US 2026/0072033 A1Creatv MicroTech, Inc.
- A method for predicting the response of metastases to immunotherapy in a metastatic colorectal cancer patient29 Jan 2026US 2026/0029397 A1Institut Claudius Regaud
- Itgb2-mediated drug delivery system1 Jan 2026US 2026/0000782 A1Twinpig Biolab Inc.
- Method of measuring level of immune suppression21 Aug 2025US 2025/0264460 A1The Johns Hopkins University
- Novel-peptide-based anticancer immunotherapeutic agent17 Jul 2025US 2025/0228951 A1Twinpig Biolab Inc.
Most cited
By later US patents
- Methods and reagents for quantitation of HLA-DR and CD11b expression on peripheral blood cells40US 6,423,505 B1Becton, Dickinson and Company · 2002
- Early detection of sepsis20US 7,465,555 B2Becton, Dickinson and Company · 2008
- Method of analyzing lymphocytes17US 7,816,135 B2Becton, Dickinson and Company · 2010
- Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies7US 6,432,404 B1ICOS Corporation · 2002
- Methods and reagents for quantitation of cell-surface molecule expression on peripheral blood cells7US 6,951,727 B2Becton, Dickinson and Company · 2005